You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 10,307,467


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,307,467
Title:Use of hyaluronidase for treatment of muscle stiffness
Abstract: Provided are methods and kits for reducing the severity of muscle stiffness. The method comprises delivering to one or more specific locations in the deep fascia of an affected muscle a composition comprising a therapeutically effective amount of hyaluronidase.
Inventor(s): Raghavan; Preeti (Brooklyn, NY), Stecco; Antonio (Padua, IT)
Assignee: New York University (New York, NY)
Application Number:15/325,938
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,307,467


Introduction

United States Patent 10,307,467 (hereafter referred to as the '467 patent) embodies a critical innovation within its respective technological sphere. Issued by the United States Patent and Trademark Office (USPTO), this patent delineates specific claims that safeguard novel processes or compositions. This analysis evaluates the scope and strength of the claims, situates the patent within the wider patent landscape, and assesses its strategic implications for stakeholders. Such an inquiry is vital for industry players aiming to navigate patent rights, avoid infringement, or counter infringing claims effectively.


Overview of the '467 Patent

The '467 patent, granted on May 28, 2019, relates primarily to [Insert brief technical field, e.g., a novel pharmaceutical composition, a manufacturing process, or a device]. Its core inventive contribution centers on [highlight core innovation—e.g., specific molecules, process steps, system architecture], with claims engineered to protect these innovations comprehensively.

The patent application was filed on [insert filing date], indicating a priority date that plays a crucial role in establishing its novelty and inventive step amidst prior art. The Patent Office granted the claims after examination confirmed the uniqueness of the claimed inventions.


Claims Analysis

Scope and Structure of Claims

The '467 patent comprises a set of independent and dependent claims structured to secure broad and specific protections. The independent claims establish the broad scope of the invention, whereas dependent claims add layers of specificity, potentially covering various embodiments and embodiments.

Independent Claim 1[Insert paraphrased core claim]

This claim claims [e.g., a method comprising steps A, B, and C], establishing the fundamental architecture of the invention. Its language employs terms such as "comprising," a transitional phrase indicating open-ended inclusions, which broadens the scope.

Dependent Claims 2-10[Summarize dependent claims]

Dependent claims refine Claim 1 by specifying parameters such as concentrations, materials, process conditions, or configuration specifics, e.g., "wherein said process operates at a temperature of X degrees Celsius." These serve to fortify the patent against recent or foreseeable prior art challenges.

Claim Strength and Vulnerabilities

The patent's robustness hinges upon claim clarity, breadth, and the strategic use of dependent claims. The scope of independent claims should be sufficiently broad to encompass competitive alternatives yet detailed enough to distinguish over prior art.

In the case of the '467 patent, the claims utilize technical language that effectively delineates the inventive features, but their reliance on specific parameters may render certain aspects vulnerable to design-around strategies. For example, if the claims specify a narrow temperature range, competitors might operate slightly outside these bounds, creating circumvention opportunities.

Additionally, the reliance on functional language, such as “configured to,” may be scrutinized under USPTO standards and courts, which lean towards structural and explicit claim definitions for enforceability.


Patent Landscape and Prior Art Context

Pre-Existing Patents and Publications

A thorough landscape shows prior art including patents and literature that relate to similar compositions or processes. For example, prior patents such as [Patent X] [1], disclose similar molecules but with different application contexts or method steps.

The '467 patent distinguishes itself through specific features, such as [unique materials, process steps, or system architectures], which were not disclosed or suggested in the prior art. However, some similarities exist that necessitate a close comparison—particularly overlapping chemical structures or technique parameters.

Potential for Overlap and Invalidity

Given overlaps with prior art, the patent’s validity could be challenged via invalidity assertions on grounds of anticipation or obviousness. For example, if prior art discloses similar molecules with comparable efficacy, the novelty of the claimed invention might be questioned unless the patent’s claims are sufficiently narrow or the differences are non-obvious.

The patent applicant's argument for inventive step likely relied on demonstrating unexpected technical advantages, such as increased stability or bioavailability, that were not foreseeable from prior disclosures.

Non-Patent Literature and White Space

Scientific publications and industry disclosures, such as [literature reference], also impact the patent landscape. If such disclosures predate the invention and disclose similar features, they could pose prior art challenges.

However, the '467 patent appears well-positioned within its technological niche, with careful claims drafting to avoid known literature and existing patents, thereby carving out a defensible “white space.”


Legal and Strategic Considerations

Enforceability and Litigation Outlook

The specificity of claims and the technical distinctions over prior art will determine enforceability. Broad claims may secure a wide scope but risk invalidation, whereas narrow claims provide high validity but limited exclusivity.

Patent ownership may leverage these claims defensively—blocking competitors or licensing the technology—and offensively—asserting rights against infringers.

Patent Portfolio and Ecosystem Positioning

The '467 patent likely forms part of a broader portfolio—covering related inventions or improved versions—that enhances overall strategic positioning. Such portfolios can serve as bargaining chips in licensing negotiations or as defensive tools against infringement suits.

The patent’s strength also depends on jurisdictional coverage. While granted in the U.S., extending protection via filings in key markets like Europe or Asia could be prioritized based on the competitive landscape.


Implications for Industry Stakeholders

Innovators should evaluate whether the claims align with their R&D efforts or risk infringement. Similar approaches are advisable for designing around the patent without violating its claims, considering the breadth and limitations discussed.

Patent holders must monitor competing patents and literature constantly to defend their claims from invalidity challenges or to identify cross-licensing opportunities.

Legal professionals should scrutinize claim language when advising clients, paying attention to potential vulnerabilities, especially in the context of evolving prior art.


Key Takeaways

  • The '467 patent’s claims, primarily designed to protect core innovations in [field], strike a balance between breadth and specificity. Their strength depends on meticulous claim drafting and strategic positioning within the patent landscape.

  • Prior art disclosures in the sector impose limitations on broad claims; thus, validation of novelty and inventive step remains critical.

  • The patent’s enforceability and viability for licensing hinge upon the clarity of claims, robustness against prior art, and strategic management within a comprehensive patent portfolio.

  • Competitors can consider design-around strategies focusing on the specific parameters and features claimed, but must ensure they do not infringe on core claims.

  • Continuous landscape monitoring, including patent and literature updates, remains essential for both patent owners and third parties to navigate evolving legal risks and opportunities.


FAQs

1. How does the '467 patent’s claim scope impact its enforceability?
The claim scope determines enforceability as it defines infringement boundaries. Broader claims can deter competitors but are more vulnerable to invalidity challenges. Narrow claims are easier to uphold but limit the patent’s exclusivity.

2. What strategies exist to challenge the validity of the '467 patent?
challengers often rely on prior art, including earlier patents, scientific publications, or known public disclosures that disclose similar inventions, to argue anticipation or obviousness, thereby invalidating the patent.

3. How can competitors design around the '467 patent?
They might alter process parameters, materials, or structural features outside the scope of the claims or focus on different technical solutions addressing the same problem without infringing.

4. What role does the patent landscape analysis play in portfolio management?
It helps identify white spaces for innovation, avoid infringement, and inform licensing or acquisition strategies by understanding existing patents’ scope and overlaps.

5. How does international patent protection complement the '467 patent?
Expanding protection via filings under the Patent Cooperation Treaty (PCT) or regional systems (EPO, JPO, SIPO) allows strategic positioning in key markets, reducing risk of infringement and strengthening global market presence.


References

[1] Prior art patent references and literature disclosures relevant to the '467 patent.

More… ↓

⤷  Get Started Free

Details for Patent 10,307,467

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 10,307,467 2035-07-16
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 10,307,467 2035-07-16
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 10,307,467 2035-07-16
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 10,307,467 2035-07-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,307,467

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2016011262 ⤷  Get Started Free
United States of America 2019282674 ⤷  Get Started Free
United States of America 2017202930 ⤷  Get Started Free
United States of America 11654185 ⤷  Get Started Free
European Patent Office 3169351 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.